Neutralizing antibodies against previously encountered influenza virus strains increase over time: a longitudinal analysis.
Identifieur interne : 000117 ( PubMed/Curation ); précédent : 000116; suivant : 000118Neutralizing antibodies against previously encountered influenza virus strains increase over time: a longitudinal analysis.
Auteurs : Matthew S. Miller [États-Unis] ; Thomas J. Gardner ; Florian Krammer ; Lauren C. Aguado ; Domenico Tortorella ; Christopher F. Basler ; Peter PaleseSource :
- Science translational medicine [ 1946-6242 ] ; 2013.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Anticorps neutralisants (immunologie), Femelle, Grippe humaine (immunologie), Grippe humaine (virologie), Humains, Jeune adulte, Mâle, Pandémies, Sous-type H1N1 du virus de la grippe A (immunologie), Sous-type H2N2 du virus de la grippe A (immunologie), Sous-type H3N2 du virus de la grippe A (immunologie), Sujet âgé, Sujet âgé de 80 ans ou plus, Études longitudinales.
- MESH :
- immunologie : Anticorps neutralisants, Grippe humaine, Sous-type H1N1 du virus de la grippe A, Sous-type H2N2 du virus de la grippe A, Sous-type H3N2 du virus de la grippe A.
- virologie : Grippe humaine.
- Adulte, Adulte d'âge moyen, Femelle, Humains, Jeune adulte, Mâle, Pandémies, Sujet âgé, Sujet âgé de 80 ans ou plus, Études longitudinales.
English descriptors
- KwdEn :
- Adult, Aged, Aged, 80 and over, Antibodies, Neutralizing (immunology), Female, Humans, Influenza A Virus, H1N1 Subtype (immunology), Influenza A Virus, H2N2 Subtype (immunology), Influenza A Virus, H3N2 Subtype (immunology), Influenza, Human (immunology), Influenza, Human (virology), Longitudinal Studies, Male, Middle Aged, Pandemics, Young Adult.
- MESH :
- chemical , immunology : Antibodies, Neutralizing.
- immunology : Influenza A Virus, H1N1 Subtype, Influenza A Virus, H2N2 Subtype, Influenza A Virus, H3N2 Subtype, Influenza, Human.
- virology : Influenza, Human.
- Adult, Aged, Aged, 80 and over, Female, Humans, Longitudinal Studies, Male, Middle Aged, Pandemics, Young Adult.
Abstract
Antigenic diversity shapes immunity in distinct and unexpected ways. This is particularly true of the humoral response generated against influenza A viruses. Although it is known that immunological memory developed against previously encountered influenza A virus strains affects the outcome of subsequent infections, exactly how sequential exposures to antigenically variant viruses shape the humoral immune response in humans remains poorly understood. To address this important question, we performed a longitudinal analysis of antibody titers against various pandemic and seasonal strains of influenza virus spanning a 20-year period (1987 to 2008) with samples from 40 individuals (birth dates, 1917 to 1952) obtained from the Framingham Heart Study. Longitudinal increases in neutralizing antibody titers were observed against previously encountered pandemic H2N2, H3N2, and H1N1 influenza A virus strains. Antibody titers against seasonal strains encountered later in life also increased longitudinally at a rate similar to that against their pandemic predecessors. Titers of cross-reactive antibodies specific to the hemagglutinin stalk domain were also investigated because they are influenced by exposure to antigenically diverse influenza A viruses. These titers rose modestly over time, even in the absence of major antigenic shifts. No sustained increase in neutralizing antibody titers against an antigenically more stable virus (human cytomegalovirus) was observed. The results herein describe a role for antigenic variation in shaping the humoral immune compartment and provide a rational basis for the hierarchical nature of antibody titers against influenza A viruses in humans.
DOI: 10.1126/scitranslmed.3006637
PubMed: 23946196
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000117
Links to Exploration step
pubmed:23946196Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Neutralizing antibodies against previously encountered influenza virus strains increase over time: a longitudinal analysis.</title><author><name sortKey="Miller, Matthew S" sort="Miller, Matthew S" uniqKey="Miller M" first="Matthew S" last="Miller">Matthew S. Miller</name><affiliation wicri:level="1"><nlm:affiliation>Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029</wicri:regionArea></affiliation></author><author><name sortKey="Gardner, Thomas J" sort="Gardner, Thomas J" uniqKey="Gardner T" first="Thomas J" last="Gardner">Thomas J. Gardner</name></author><author><name sortKey="Krammer, Florian" sort="Krammer, Florian" uniqKey="Krammer F" first="Florian" last="Krammer">Florian Krammer</name></author><author><name sortKey="Aguado, Lauren C" sort="Aguado, Lauren C" uniqKey="Aguado L" first="Lauren C" last="Aguado">Lauren C. Aguado</name></author><author><name sortKey="Tortorella, Domenico" sort="Tortorella, Domenico" uniqKey="Tortorella D" first="Domenico" last="Tortorella">Domenico Tortorella</name></author><author><name sortKey="Basler, Christopher F" sort="Basler, Christopher F" uniqKey="Basler C" first="Christopher F" last="Basler">Christopher F. Basler</name></author><author><name sortKey="Palese, Peter" sort="Palese, Peter" uniqKey="Palese P" first="Peter" last="Palese">Peter Palese</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2013">2013</date><idno type="RBID">pubmed:23946196</idno><idno type="pmid">23946196</idno><idno type="doi">10.1126/scitranslmed.3006637</idno><idno type="wicri:Area/PubMed/Corpus">000117</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000117</idno><idno type="wicri:Area/PubMed/Curation">000117</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000117</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Neutralizing antibodies against previously encountered influenza virus strains increase over time: a longitudinal analysis.</title><author><name sortKey="Miller, Matthew S" sort="Miller, Matthew S" uniqKey="Miller M" first="Matthew S" last="Miller">Matthew S. Miller</name><affiliation wicri:level="1"><nlm:affiliation>Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029</wicri:regionArea></affiliation></author><author><name sortKey="Gardner, Thomas J" sort="Gardner, Thomas J" uniqKey="Gardner T" first="Thomas J" last="Gardner">Thomas J. Gardner</name></author><author><name sortKey="Krammer, Florian" sort="Krammer, Florian" uniqKey="Krammer F" first="Florian" last="Krammer">Florian Krammer</name></author><author><name sortKey="Aguado, Lauren C" sort="Aguado, Lauren C" uniqKey="Aguado L" first="Lauren C" last="Aguado">Lauren C. Aguado</name></author><author><name sortKey="Tortorella, Domenico" sort="Tortorella, Domenico" uniqKey="Tortorella D" first="Domenico" last="Tortorella">Domenico Tortorella</name></author><author><name sortKey="Basler, Christopher F" sort="Basler, Christopher F" uniqKey="Basler C" first="Christopher F" last="Basler">Christopher F. Basler</name></author><author><name sortKey="Palese, Peter" sort="Palese, Peter" uniqKey="Palese P" first="Peter" last="Palese">Peter Palese</name></author></analytic><series><title level="j">Science translational medicine</title><idno type="eISSN">1946-6242</idno><imprint><date when="2013" type="published">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Antibodies, Neutralizing (immunology)</term><term>Female</term><term>Humans</term><term>Influenza A Virus, H1N1 Subtype (immunology)</term><term>Influenza A Virus, H2N2 Subtype (immunology)</term><term>Influenza A Virus, H3N2 Subtype (immunology)</term><term>Influenza, Human (immunology)</term><term>Influenza, Human (virology)</term><term>Longitudinal Studies</term><term>Male</term><term>Middle Aged</term><term>Pandemics</term><term>Young Adult</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Anticorps neutralisants (immunologie)</term><term>Femelle</term><term>Grippe humaine (immunologie)</term><term>Grippe humaine (virologie)</term><term>Humains</term><term>Jeune adulte</term><term>Mâle</term><term>Pandémies</term><term>Sous-type H1N1 du virus de la grippe A (immunologie)</term><term>Sous-type H2N2 du virus de la grippe A (immunologie)</term><term>Sous-type H3N2 du virus de la grippe A (immunologie)</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Études longitudinales</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Neutralizing</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Anticorps neutralisants</term><term>Grippe humaine</term><term>Sous-type H1N1 du virus de la grippe A</term><term>Sous-type H2N2 du virus de la grippe A</term><term>Sous-type H3N2 du virus de la grippe A</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term><term>Influenza A Virus, H2N2 Subtype</term><term>Influenza A Virus, H3N2 Subtype</term><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Female</term><term>Humans</term><term>Longitudinal Studies</term><term>Male</term><term>Middle Aged</term><term>Pandemics</term><term>Young Adult</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Femelle</term><term>Humains</term><term>Jeune adulte</term><term>Mâle</term><term>Pandémies</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Études longitudinales</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Antigenic diversity shapes immunity in distinct and unexpected ways. This is particularly true of the humoral response generated against influenza A viruses. Although it is known that immunological memory developed against previously encountered influenza A virus strains affects the outcome of subsequent infections, exactly how sequential exposures to antigenically variant viruses shape the humoral immune response in humans remains poorly understood. To address this important question, we performed a longitudinal analysis of antibody titers against various pandemic and seasonal strains of influenza virus spanning a 20-year period (1987 to 2008) with samples from 40 individuals (birth dates, 1917 to 1952) obtained from the Framingham Heart Study. Longitudinal increases in neutralizing antibody titers were observed against previously encountered pandemic H2N2, H3N2, and H1N1 influenza A virus strains. Antibody titers against seasonal strains encountered later in life also increased longitudinally at a rate similar to that against their pandemic predecessors. Titers of cross-reactive antibodies specific to the hemagglutinin stalk domain were also investigated because they are influenced by exposure to antigenically diverse influenza A viruses. These titers rose modestly over time, even in the absence of major antigenic shifts. No sustained increase in neutralizing antibody titers against an antigenically more stable virus (human cytomegalovirus) was observed. The results herein describe a role for antigenic variation in shaping the humoral immune compartment and provide a rational basis for the hierarchical nature of antibody titers against influenza A viruses in humans. </div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23946196</PMID><DateCompleted><Year>2014</Year><Month>03</Month><Day>05</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1946-6242</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><Issue>198</Issue><PubDate><Year>2013</Year><Month>Aug</Month><Day>14</Day></PubDate></JournalIssue><Title>Science translational medicine</Title><ISOAbbreviation>Sci Transl Med</ISOAbbreviation></Journal><ArticleTitle>Neutralizing antibodies against previously encountered influenza virus strains increase over time: a longitudinal analysis.</ArticleTitle><Pagination><MedlinePgn>198ra107</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/scitranslmed.3006637</ELocationID><Abstract><AbstractText>Antigenic diversity shapes immunity in distinct and unexpected ways. This is particularly true of the humoral response generated against influenza A viruses. Although it is known that immunological memory developed against previously encountered influenza A virus strains affects the outcome of subsequent infections, exactly how sequential exposures to antigenically variant viruses shape the humoral immune response in humans remains poorly understood. To address this important question, we performed a longitudinal analysis of antibody titers against various pandemic and seasonal strains of influenza virus spanning a 20-year period (1987 to 2008) with samples from 40 individuals (birth dates, 1917 to 1952) obtained from the Framingham Heart Study. Longitudinal increases in neutralizing antibody titers were observed against previously encountered pandemic H2N2, H3N2, and H1N1 influenza A virus strains. Antibody titers against seasonal strains encountered later in life also increased longitudinally at a rate similar to that against their pandemic predecessors. Titers of cross-reactive antibodies specific to the hemagglutinin stalk domain were also investigated because they are influenced by exposure to antigenically diverse influenza A viruses. These titers rose modestly over time, even in the absence of major antigenic shifts. No sustained increase in neutralizing antibody titers against an antigenically more stable virus (human cytomegalovirus) was observed. The results herein describe a role for antigenic variation in shaping the humoral immune compartment and provide a rational basis for the hierarchical nature of antibody titers against influenza A viruses in humans. </AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Matthew S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gardner</LastName><ForeName>Thomas J</ForeName><Initials>TJ</Initials></Author><Author ValidYN="Y"><LastName>Krammer</LastName><ForeName>Florian</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Aguado</LastName><ForeName>Lauren C</ForeName><Initials>LC</Initials></Author><Author ValidYN="Y"><LastName>Tortorella</LastName><ForeName>Domenico</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Basler</LastName><ForeName>Christopher F</ForeName><Initials>CF</Initials></Author><Author ValidYN="Y"><LastName>Palese</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>T32 AI007647</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN26620070010C</GrantID><Agency>PHS HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01 HC025195</GrantID><Acronym>HC</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AI085306</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN266200700010C</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AI085306</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Transl Med</MedlineTA><NlmUniqueID>101505086</NlmUniqueID><ISSNLinking>1946-6234</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053118" MajorTopicYN="N">Influenza A Virus, H1N1 Subtype</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053121" MajorTopicYN="N">Influenza A Virus, H2N2 Subtype</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053122" MajorTopicYN="N">Influenza A Virus, H3N2 Subtype</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>8</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>8</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>3</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23946196</ArticleId><ArticleId IdType="pii">5/198/198ra107</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.3006637</ArticleId><ArticleId IdType="pmc">PMC4091683</ArticleId><ArticleId IdType="mid">NIHMS609901</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Curr Top Microbiol Immunol. 2008;325:297-313</Citation><ArticleIdList><ArticleId IdType="pubmed">18637513</ArticleId></ArticleIdList></Reference><Reference><Citation>J Exp Med. 1953 Dec;98(6):641-56</Citation><ArticleIdList><ArticleId IdType="pubmed">13109114</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2007 Nov 8;357(19):1903-15</Citation><ArticleIdList><ArticleId IdType="pubmed">17989383</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2012 Jun 5;109(23):9047-52</Citation><ArticleIdList><ArticleId IdType="pubmed">22615367</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 1958 May 15;258(20):1016-7</Citation><ArticleIdList><ArticleId IdType="pubmed">13541705</ArticleId></ArticleIdList></Reference><Reference><Citation>Trans Assoc Am Physicians. 1953;66:231-9</Citation><ArticleIdList><ArticleId IdType="pubmed">13136267</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2011 Aug 12;333(6044):850-6</Citation><ArticleIdList><ArticleId IdType="pubmed">21798894</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Invest. 2010 May;120(5):1663-73</Citation><ArticleIdList><ArticleId IdType="pubmed">20389023</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 1979 Jan 6;1(8106):33-5</Citation><ArticleIdList><ArticleId IdType="pubmed">83475</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Transl Med. 2013 Feb 6;5(171):171ra19</Citation><ArticleIdList><ArticleId IdType="pubmed">23390249</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2013 Apr;87(8):4728-37</Citation><ArticleIdList><ArticleId IdType="pubmed">23408625</ArticleId></ArticleIdList></Reference><Reference><Citation>Herpesviridae. 2011 Apr 07;2(1):6</Citation><ArticleIdList><ArticleId IdType="pubmed">21473750</ArticleId></ArticleIdList></Reference><Reference><Citation>MBio. 2011;2(5). pii: e00150-11. doi: 10.1128/mBio.00150-11</Citation><ArticleIdList><ArticleId IdType="pubmed">21878571</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Pathog. 2012;8(7):e1002802</Citation><ArticleIdList><ArticleId IdType="pubmed">22829765</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Pathog. 2010 Jan;6(1):e1000745</Citation><ArticleIdList><ArticleId IdType="pubmed">20126449</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2012 Dec 21;151(7):1569-80</Citation><ArticleIdList><ArticleId IdType="pubmed">23260143</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2013 Jan 1;207(1):98-105</Citation><ArticleIdList><ArticleId IdType="pubmed">23087428</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2012;7(8):e43603</Citation><ArticleIdList><ArticleId IdType="pubmed">22928001</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2012 Jun;86(11):6334-40</Citation><ArticleIdList><ArticleId IdType="pubmed">22457520</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2010 Jul 13;107(28):12599-604</Citation><ArticleIdList><ArticleId IdType="pubmed">20616031</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Vaccine Immunol. 2013 Apr;20(4):540-50</Citation><ArticleIdList><ArticleId IdType="pubmed">23389931</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2002 Dec 13;298(5601):2199-202</Citation><ArticleIdList><ArticleId IdType="pubmed">12481138</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2004 Jul 16;305(5682):371-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15218094</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2012 May;86(10):5774-81</Citation><ArticleIdList><ArticleId IdType="pubmed">22398287</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2012 Feb 14;109(7):2573-8</Citation><ArticleIdList><ArticleId IdType="pubmed">22308500</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 1966 Aug;97(2):177-83</Citation><ArticleIdList><ArticleId IdType="pubmed">5921310</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2011 Apr 15;52(8):1003-9</Citation><ArticleIdList><ArticleId IdType="pubmed">21460314</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2012 Oct;86(19):10302-7</Citation><ArticleIdList><ArticleId IdType="pubmed">22787225</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2013 Apr;87(8):4486-95</Citation><ArticleIdList><ArticleId IdType="pubmed">23388717</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Immunol. 2013;31:705-42</Citation><ArticleIdList><ArticleId IdType="pubmed">23330954</ArticleId></ArticleIdList></Reference><Reference><Citation>J Exp Med. 2011 Jan 17;208(1):181-93</Citation><ArticleIdList><ArticleId IdType="pubmed">21220454</ArticleId></ArticleIdList></Reference><Reference><Citation>Exp Gerontol. 2007 Jun;42(6):563-70</Citation><ArticleIdList><ArticleId IdType="pubmed">17337145</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2010 Jun 1;50(11):1487-92</Citation><ArticleIdList><ArticleId IdType="pubmed">20415539</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Immunol. 2012 May 08;3:87</Citation><ArticleIdList><ArticleId IdType="pubmed">22586427</ArticleId></ArticleIdList></Reference><Reference><Citation>J Exp Med. 1966 Sep 1;124(3):347-61</Citation><ArticleIdList><ArticleId IdType="pubmed">5926092</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2011 Aug 12;333(6044):843-50</Citation><ArticleIdList><ArticleId IdType="pubmed">21737702</ArticleId></ArticleIdList></Reference><Reference><Citation>J Exp Med. 1966 Sep 1;124(3):331-45</Citation><ArticleIdList><ArticleId IdType="pubmed">5922742</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000117 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000117 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= H2N2V1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:23946196
|texte= Neutralizing antibodies against previously encountered influenza virus strains increase over time: a longitudinal analysis.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:23946196" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a H2N2V1
| This area was generated with Dilib version V0.6.33. |  |